Page 1

● ● Almirall delivers robust H1 performance and increases full - year guidance ● almirall feel the science ● Press Release Robust business performance with significant growth in Core EBITDA : Core Net Sales € 415.5 MM ( + 8 % year - on - year ) and Core EBITDA reached € 125.6 MM , ( + 40.4 % year - on - year ) Barcelona , Spain July , 26 2021 The company is upgrading its Core EBITDA Guidance for 2021 to € 195 MM - € 215 MM ( previously € 190 MM- € 210 MM ) The R & D pipeline continues to drive future value with expected milestones in H2 2021 including the launch in Europe of Klisyri® , an innovative treatment for actinic keratosis ; the approval of WynzoraⓇi Cream , a topical treatment of mild to moderate psoriasis vulgaris , in other European countries after having been granted approval in France , and initial Phase III data for lebrikizumab for the treatment of moderate - to - severe atopic dermatitis Summary of results H1 Almirall strengthens its late - stage pipeline after entering into a license and distribution agreement with Kaken Pharmaceutical that grants the company exclusive rights for the development and commercialisation of the topical formulation of efinaconazole in Europe Almirall , S.A. ( ALM ) , the global biopharmaceutical company based in Barcelona , has announced its H1 2021 financial results . Core Net Sales * reached € 415.5 MM , an 8 % year - on - year increase with positive contribution by Growth Drivers Normalised net income € 57.8 MM Core EBITDA ** increased 40.4 % year - on - year to € 125.6 MM driven by positive contribution from Growth Drivers * Core Net Sales excludes AstraZeneca Deferred Income ** Core EBITDA excludes AstraZeneca Deferred Income and Other Income Net Loss of € 42.8 MM due to an impairment of c . € 100 MM for the carrying value of the intangible asset for Seysara® ( € 69 MM ) , the US Legacy Portfolio ( € 22 MM ) , and the Bioniz option payment which was not exercised ( € 12 MM ) Operating Cash Flow reached € 109.8 MM